BlueConic and Nagarro Partner to Deliver Transformational Value to Enterprise CDP Adopters
2.2.2021 16:02:00 EET | Business Wire | Press release
BlueConic, the world’s leading pure-play customer data platform (CDP), and Nagarro, a global leader in digital engineering and technology solutions, today announced a strategic partnership to help enterprise organizations deploy BlueConic with rapid time-to-value and for maximal, long-term impact of the platform. Nagarro’s deep expertise in BlueConic’s technology, combined with the implementation and utilization best practices already successfully pioneered by BlueConic, will ensure joint customers get transformational value from their investment.
Making first-party data a strategic asset is the future of all businesses. Yet accessing unified, actionable customer data can be challenging for the innovative disruptors and the established stalwarts alike. As these companies embrace the need for business transformation, they are confronting the pain of trying to use legacy technologies – each with its own unique way of storing data and recognizing customers – to support a fast moving, end-to-end customer experience.
Investment in a customer data platform like BlueConic represents an opportunity for transformation-minded organizations to differentiate from their competitors by putting customer relationships at the center of their growth strategies. Through the partnership with Nagarro, BlueConic customers all over the world will get the industry, regional, and technology expertise they need to realize the full benefit of BlueConic, as well as all the other major marketing technology platforms and data solutions that they use to create competitive advantage in their industries.
“BlueConic’s customer data platform is one of the world’s best. Partnering BlueConic with Nagarro’s agile delivery capabilities, brands, and companies worldwide are maximizing their competitiveness, while future-proofing the IT architecture and minimizing IT integration costs,” says Ram Reddy, CTO of Nagarro.
“Nagarro’s best-in-class digital services and agile delivery capabilities are an important factor in helping our customers maximize the value of our customer data platform and realize the type of transformation they will need to stay competitive over the next decade,” explains Cory Munchbach, COO of BlueConic. “The Nagarro team shares our commitment to delivering a customer experience that is predicated on expertise and empathy as our customers confront relentless change in the global market in 2021 and beyond.”
About Nagarro
Nagarro is a global digital engineering leader with a full-service offering. Nagarro specializes in “change the business” technology services, including digital product engineering, e-commerce and customer experience services, Artificial Intelligence and Machine Learning capabilities, cloud and IoT solutions, and consulting on next-generation ERP. The company has a broad and long-standing international customer base, primarily in Central Europe, particularly Germany, and in North America. This includes a number of global blue-chip companies and leading independent software vendors (ISVs), other market and industry leaders, and public sector clients. In total, the group employs over 8,400 people worldwide (as of June 30, 2020). Further information is available at www.nagarro.com.
About BlueConic
BlueConic, the leading pure-play customer data platform, liberates companies’ first-party data from disparate systems and makes it accessible wherever and whenever it is required to transform customer relationships and drive business growth. Over 300 companies worldwide, including Hearst Newspapers, Heineken, ING, T-Mobile, UEFA, and VF Corp, use BlueConic to unify data into persistent, individual-profiles, and then activate it across customer touchpoints and systems in support of a wide range of growth-focused initiatives, including customer lifecycle orchestration, modeling and analytics, digital products and experiences, audience-based monetization, and more. BlueConic is a global company with offices in the US and Europe. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005069/en/
Contact information
North America PR for BlueConic
Stephanie Hadley, 617-650-8147
steph.hadley@hadleypr.com
Europe PR for BlueConic
Karolina Throssell, 07855 751005
Karolina@iden.global
www.iden.global
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom